Digest Network Come funziona
Network
/
Società
Pa
Non verificato

Paradigm Therapeutics, Inc.

Di cosa scriviamo

AgricolturaEcologia/Salute ambientaleFitnessMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati
Press Release cover image
22/10/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
Fonte
Paradigm Therapeutics, Inc.
Emittente
PR News Wire
1.00
0
Press Release cover image
13/10/2026
Salute
Fitness
Fiere
Eventi
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
Fonte
Paradigm Therapeutics, Inc.
Emittente
PR News Wire
1.00
0
06/05/2025
Farmaceutica
Sanità
Banca
Finanza
Mutui
Risparmio/Affari personali
Leasing
Gestione dei titoli obbligazionari
Fondi di investimento
Euro-obbligazioni
Biologia
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa(TM)), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
Fonte
Paradigm Therapeutics, Inc.
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0